Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus“ in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40MGC | ISIN: US87164U5083 | Ticker-Symbol: SFY0
NASDAQ
06.11.24
21:59 Uhr
2,000 US-Dollar
-0,010
-0,50 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
THERIVA BIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
THERIVA BIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0000,00006.11.

Aktuelle News zur THERIVA BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrTheriva Biologics, Inc. - 8-K, Current Report2
FrWhat's Going On With Theriva Biologics Stock Friday?11
FrPre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma511CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15. VS...
► Artikel lesen
31.10.Theriva Biologics, Inc.: Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant918Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing...
► Artikel lesen
16.10.Theriva Biologics gains EU orphan drug status for eye cancer treatment3
16.10.Theriva Biologics erhält EU-Orphan-Drug-Status für Augenkrebs-Behandlung3
16.10.Theriva Biologics, Inc. - 8-K, Current Report2
16.10.Theriva Biologics, Inc.: Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma217ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), ("Theriva" or the "Company"), a clinical-stage company developing therapeutics designed to treat cancer and...
► Artikel lesen
03.10.Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients3
03.10.Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients1
03.10.Theriva reports progress in phase 1b/2a trial of SYN-0042
03.10.Theriva Biologics, Inc. - 8-K, Current Report6
03.10.Theriva Biologics, Inc.: Theriva Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients205DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients into Cohort 3ROCKVILLE, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics...
► Artikel lesen
02.10.Synthetic Biologics stock plunges to 52-week low of $1.242
02.10.Aktie von Synthetic Biologics fällt auf 52-Wochen-Tief von 1,24 US-Dollar3
27.09.Theriva Biologics dips 11%, prices 2.5M equity offering2
27.09.Theriva Biologics, Inc.: Theriva Biologics Announces Pricing of $2.5 Million Public Offering9
25.09.Synthetic Biologics-Aktie stürzt auf 52-Wochen-Tief von 2,66 US-Dollar1
25.09.Synthetic Biologics stock plunges to 52-week low of $2.661
23.09.Theriva Biologics, Inc. - S-1/A, General form for registration of securities3
Seite:  Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1